Literature DB >> 12850435

Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors.

Deniz Kirik1, Anders Björklund.   

Abstract

Defective handling of proteins is a central feature of major neurodegenerative diseases. The discovery that neuronal dysfunction or degeneration can be caused by mutations in single cellular proteins has given new opportunities to model the underlying disease processes by genetic modification of cells in vitro or by generation of transgenic animals carrying the disease-causing gene. Recent developments in recombinant viral-vector technology have opened up an interesting alternative possibility, based on direct gene transfer to selected subregions or subsets of neurons in the brain. Using the highly efficient adeno-associated virus or lentivirus vectors, recent reports have shown that overexpression of mutated human huntingtin or alpha-synuclein in neurons in the striatum or substantia nigra induces progressive neuropathology and neurodegeneration, similar to that seen in Huntington's and Parkinson's diseases. Targeted overexpression of disease-causing genes by recombinant viral vectors provides a new and highly flexible approach for in vivo modeling of neurodegenerative diseases, not only in mice and rats but also in primates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12850435     DOI: 10.1016/S0166-2236(03)00164-4

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  18 in total

Review 1.  Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions.

Authors:  Jean-Luc Dreyer
Journal:  Mol Biotechnol       Date:  2011-02       Impact factor: 2.695

Review 2.  Human gene therapy and imaging in neurological diseases.

Authors:  Andreas H Jacobs; Alexandra Winkler; Maria G Castro; Pedro Lowenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

Review 3.  Versatile somatic gene transfer for modeling neurodegenerative diseases.

Authors:  Ronald L Klein; David B Wang; Michael A King
Journal:  Neurotox Res       Date:  2009-08-11       Impact factor: 3.911

4.  Gene transfer engineering for astrocyte-specific silencing in the CNS.

Authors:  N Merienne; A Delzor; A Viret; N Dufour; M Rey; P Hantraye; N Déglon
Journal:  Gene Ther       Date:  2015-06-05       Impact factor: 5.250

5.  Spinal cord injury and the neuron-intrinsic regeneration-associated gene program.

Authors:  Nitish D Fagoe; Jessica van Heest; Joost Verhaagen
Journal:  Neuromolecular Med       Date:  2014-10-01       Impact factor: 3.843

6.  The prion hypothesis of Parkinson's disease.

Authors:  Yaping Chu; Jeffrey H Kordower
Journal:  Curr Neurol Neurosci Rep       Date:  2015-05       Impact factor: 5.081

7.  Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.

Authors:  Christophe Lo Bianco; Bernard L Schneider; Matthias Bauer; Ali Sajadi; Alexis Brice; Takeshi Iwatsubo; Patrick Aebischer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-02       Impact factor: 11.205

8.  Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates.

Authors:  Hemraj B Dodiya; Tomas Bjorklund; James Stansell; Ronald J Mandel; Deniz Kirik; Jeffrey H Kordower
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

9.  AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.

Authors:  Nicholas R Franich; Helen L Fitzsimons; Dahna M Fong; Matthias Klugmann; Matthew J During; Deborah Young
Journal:  Mol Ther       Date:  2008-03-25       Impact factor: 11.454

10.  GFAP reactivity, apolipoprotein E redistribution and cholesterol reduction in human astrocytes treated with alpha-synuclein.

Authors:  Andrew O Koob; Amy D Paulino; Eliezer Masliah
Journal:  Neurosci Lett       Date:  2009-11-20       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.